Table 1.

Patient characteristics

Sipuleucel-T (n = 117)Control (n = 59)
Age, years [median (min, max)]64 (48,79)67 (47,78)
Race (n,%)  
Caucasian105 (89.7)54 (91.5)
African—American9 (7.7)3 (5.1)
Hispanic2 (1.7)1 (1.7)
Other1 (0.9)1 (1.7)
ECOG performance status (n,%)
0109 (94.8)57 (98.3)
16 (5.2)1 (1.7)
Gleason score (n,%)
≤ 634 (30.1)15 (26.3)
≥ 779 (69.9)42 (73.7)
Prior adjuvant hormone therapy (n,%)
Yes21 (17.9)9 (15.3)
No96 (82.1)49 (83.1)
Prior radiation therapy (n,%)
None45 (38.5)23 (39.0)
Adjuvant20 (17.1)8 (13.6)
Salvage52 (44.4)28 (47.5)
Median PSA, ng/mL (min, max)
Highest ever2.3 (0.8, 33.0)2.3 (0.8, 20.5)
Prior to LHRH-a2.1 (0.8, 16.9)2.7 (0.8, 20.5)
Prior to randomization0.09 (0.010–1.00)0.090 (0.010–1.00)

Abbreviations: ECOG, Eastern Cooperative Oncology Group; LHRH-a, luteinizing hormone-releasing hormone-analogue; PSA, prostate-specific antigen.